Primer probe combination and application thereof in preparation of kit for identifying mycoplasma synoviae wild strain and MS-H strain
By designing a combination of primer probes based on SNP sites and using real-time fluorescence quantitative PCR technology, the problem of distinguishing Mycoplasma synovial sacculus wild strain and temperature-sensitive vaccine strain in the prior art is solved, and the MS-H vaccine strain is realized Accurate identification from wild virus strains, especially after the vaccine strain resumes mutations, improves the sensitivity and specificity of the detection.
Patent Information
- Application Number
- CN202411083685.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-08
AI Technical Summary
Existing methods are difficult to accurately distinguish between Mycoplasma synovial sacculus and the temperature-sensitive vaccine strain (MS-H strain), especially after the vaccine strain returns to mutation, resulting in false positive results, and the operation is complicated and time-consuming, so it cannot be effective. Distinguish MS-H from other Australian wild plants.
A primer probe combination based on the SNP site between the MS-H vaccine strain and the wild virus strain was designed. Using real-time fluorescence quantitative PCR technology, the A/G variants at position 131 of the MSH_02330 gene were identified and specific. The probe recognizes vaccine strains and wild virus strains, providing a kit that can distinguish MS-H vaccine strains (including ts-response mutant strains) from wild virus strains.
Achieve high sensitivity, specificity and repetitive identification of MS-H vaccine strains and wild virus strains, which can accurately distinguish and exclude the influence of ts-response mutant strains, and is suitable for identification of isolated and cultured MS isolates and chicken groups. Evaluation of replication efficiency of medium vaccine strains and monitoring of wild poison infection.
Smart Images

Figure CN118910294A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedical technology, and specifically relates to a primer-probe combination and an application thereof in preparing a kit for distinguishing wild strains and MS-H strains of Mycoplasma synoviae, and in particular to a real-time fluorescence quantitative PCR kit for distinguishing wild strains and vaccine strains (MS-H strains) of Mycoplasma synoviae and an application thereof. Background Art
[0002] Mycoplasma synoviae (MS) infection mainly occurs in chickens and turkeys. Clinical symptoms mainly include subclinical infection of the upper respiratory tract, infectious synovitis and abnormal eggshell tip. The disease can be transmitted vertically through eggs and horizontally through the respiratory tract. Once a flock is infected, it is very difficult to eradicate, so the disease spreads in the flock for a long time, leading to problems such as low feed utilization, slow growth and development, increased culling rate and decreased egg production. In addition, MS is easily mixed with other pathogens such as Newcastle disease virus and infectious bronchitis virus, which aggravates the disease, increases mortality and causes serious economic losses.
[0003] In recent years, MS infection in chickens in my country's poultry farming industry has become increasingly serious, affecting yellow-feathered broilers, white-feathered broilers, broiler chickens and laying hens. Currently, population purification faces great difficulties and high costs. At the same time, with the trend of antibiotic-free farming, the use of antibiotics is also strictly restricted. Therefore, vaccine immunization has become an important means of controlling MS. At present, the main vaccines that have been registered and put into clinical use worldwide include the temperature-sensitive live vaccine Vax produced by Australian Bioresources MS (MS-H strain) and the live attenuated vaccine Nobilis MS Live (MS1 strain) produced by MSD. In China, the temperature-sensitive type (ts + )Live vaccine (MS-H strain) [(2017) Foreign Veterinary Drug Certificate No. 33].
[0004] The application of live vaccines can not only produce competitive exclusion effects on wild-type virus infection by colonizing the upper respiratory tract, but also produce effective mucosal immune responses to achieve the effect of blocking wild-type virus infection. Therefore, live vaccines play an important role in the comprehensive prevention and control of MS infection. However, the competitive exclusion effect of live vaccines on wild-type virus infection is not achieved overnight. After infection with wild-type virus strains, they usually coexist with vaccine strains in chickens for a long period of time. The final blocking effect depends on the difference in the competitive ability of both parties. Therefore, when monitoring wild-type virus infection in live vaccine-immunized chickens, a method (DIVA) that can accurately distinguish between vaccine immunity and wild-type virus infection is needed.
[0005] Currently, a variety of methods have been reported to distinguish between MS-H vaccine strains and wild-type MS strains, such as target gene sequencing and restriction fragment length polymorphism analysis (PCR-RFLP) based on sequence analysis of the PRR and RⅢ regions of the vlhA gene (EL-GAZZAR MM, WETZEL AN, RAVIV Z. The genotyping potential of the Mycoplasma synoviae vlhA gene [J]. Avian diseases, 2012, 56 (4): 711-9.), or MLST typing based on housekeeping genes (EL-GAZZAR M, GHANEM M, MCDONALD K, et al. Development of Multilocus Sequence Typing (MLST) for Mycoplasma synoviae [J]. Avian diseases, 2017, 61 (1): 25-32.). However, these methods usually require sequencing, which is time-consuming and labor-intensive, and cannot distinguish between MS-H and other wild-type Australian strains.In addition, there are dual probe detection methods based on the SNP at position 367 of the obg gene discovered by Shahid MA et al. (SHAHID MA, MARKHAM PF, MARKHAM JF, et al. Mutations in GTP binding protein Obg of Mycoplasma synoviae vaccine strain MS-H: implications in temperature-sensitivity phenotype[J]. PloS one, 2013, 8(9): e73954.) (ZHANG Xiaorong, CHEN Mengyao, WU Yantao, et al. A real-time fluorescence quantitative PCR kit for distinguishing wild strains of Mycoplasma synoviae and vaccine strains MS-H, CN110699469B[P / OL]. 2022-08-09].), high-resolution melting curve method (HRM), mismatch amplification mutation analysis method (MAMA), and oppF gene 468 frameshift method discovered by ZHU L et al. (ZHU L, KONSAK BM, OLAOGUN OM, et al. al.Identification of a new genetic marker in Mycoplasma synoviae vaccine strain MS-H and development of astrategy using polymerase chain reaction and high-resolution melting curve analysis for differentiating MS-H from field strains[J].Veterinarymicrobiology,2017,210(49-55.) established HRM method and indirect ELISA method. These methods are simple and fast to operate and have good sensitivity.However, some studies in recent years have found that after the clinical use of MS-H vaccine, the obg gene and oppF gene of some MS-H reisolated strains will revert to the wild type (KORDAFSHARI S, SHIL P, MARENDA MS, et al. Preliminary comparative analysis of the genomes of selected fieldreisolates of the Mycoplasma synoviae vaccine strain MS-H reveals both stable and unstable mutations after passage in vivo[J]. BMC genomics, 2020, 21(1): 598.), resulting in the loss of temperature sensitivity (ts. - ), these ts - The horizontal transmission of reverted mutant strains in chicken flocks will not lead to higher pathogenicity or more severe clinical symptoms (KLOSE SM, OMOTAINSE OS, ZARE S, et al. Virulence factors of Mycoplasma synoviae: Three genes influencing colonization, immunogenicity, and transmissibility [J]. Frontiers in microbiology, 2022, 13 (1042212.), but these reverted mutant vaccine strains will greatly interfere with the monitoring of wild virus infection and produce false positive results in some wild virus detection.
[0006] Therefore, there is an urgent need to find new gene targets and establish specific identification and detection methods that can simultaneously distinguish between MS wild-type viruses and MS-H vaccine viruses, including revertant mutants, as an effective supplement to the existing identification and detection methods based on the obg gene and oppF gene SNP sites, or even completely replace the existing methods. Summary of the invention
[0007] Purpose of the invention: The technical problem to be solved by the present invention is to provide a primer-probe combination designed based on the SNP site between the MS-H vaccine strain and the wild strain for use in the preparation of a kit for identifying the wild strain and temperature-sensitive vaccine strain of Mycoplasma synoviae.
[0008] The technical problem that the present invention also aims to solve is to provide a primer-probe combination for identifying wild strains of Mycoplasma synoviae and temperature-sensitive vaccine strains and their reverse mutants.
[0009] The final technical problem to be solved by the present invention is to provide a kit that can quantitatively detect and distinguish wild strains of Mycoplasma synoviae and temperature-sensitive vaccine strains.
[0010] Technical solution: In order to solve the above technical problems, the present invention provides an application of a primer-probe combination designed based on a SNP site between an MS-H vaccine strain and a wild strain in the preparation of a kit for identifying a wild strain of Mycoplasma synoviae and a temperature-sensitive vaccine strain, wherein the SNP site is at position 131 of the MSH_02330 gene, the polymorphic site of the wild strain of Mycoplasma synoviae is G, and the polymorphic site of the temperature-sensitive vaccine strain is A. The primer pair sequences in the primer-probe combination are shown in SEQ ID NO.1 and SEQ ID NO.2, and the probe sequences in the primer-probe combination are shown in SEQ ID NO.3 and SEQ ID NO.4, respectively.
[0011] The present invention also includes a primer-probe combination for identifying wild strains of Mycoplasma synoviae and temperature-sensitive vaccine strains. The primer pair sequences in the primer-probe combination are shown in SEQ ID NO.1 and SEQ ID NO.2, and the probe sequences in the primer-probe combination are shown in SEQ ID NO.3 and SEQ ID NO.4, respectively.
[0012] The present invention also includes a kit for identifying wild strains and temperature-sensitive vaccine strains of Mycoplasma synoviae, which comprises the primer-probe combination.
[0013] The 5' ends of the probes are respectively labeled with FAM and VIC reporter groups, and the 3' ends are labeled with MGB fluorescence quenching groups.
[0014] The kit also includes a 2×qPCR amplification premix and a positive standard.
[0015] The positive standard comprises a plasmid containing the MSH_02330 gene fragment of the wild strain WVU 1853 and the vaccine strain MS-H of Mycoplasma synoviae.
[0016] Among them, the sequences of the MSH_02330 gene fragments of the wild strain WVU 1853 and the vaccine strain MS-H are shown in SEQ ID NO.8 and SEQ ID NO.9.
[0017] When used to identify wild-type strains of Mycoplasma synoviae and temperature-sensitive vaccine strains, follow the steps below:
[0018] (1) Extracting total DNA from the sample to be tested;
[0019] (2) establishing a fluorescence quantitative standard curve, using the positive standard plasmid gradient dilution as a template, and performing fluorescence quantitative PCR amplification with the primer probe combination described in claim 2 to establish a standard curve;
[0020] (3) using the total DNA extracted in step (1) as a template and performing fluorescent quantitative PCR amplification using the primer pair and probe;
[0021] (4) Automatically detect and collect fluorescent signals during the PCR reaction. The wild-type strain is identified as having a signal only in the FAM channel, and the MS-H vaccine is identified as having a signal only in the VIC channel. At the same time, the pathogen content in the sample to be tested is quantified according to the standard curve.
[0022] The reaction conditions of the fluorescence quantitative PCR in step (2) are: 95°C for 5 min; 95°C for 10 s, 60°C for 30 s, 40 cycles, and the signal is collected at the 60°C for 30 s stage.
[0023] The PCR amplification system of step (2) is 20 μL, which contains 10 μL 2×qPCR Probe MasterMix, 0.1-1.8 μL 522899-F, 0.1-1.8 μL 522899-R, 0.2-0.5 μL 522899-PW, 0.2-0.5 μL 522899-PV, 2 μL template DNA and sterile water.
[0024] Preferably, the PCR amplification system of step (2) is 20 μL, including 10 μL 2×qPCR Probe MasterMix, 0.1 μL 522899-F2, 0.1 μL 522899-R3, 0.2 μL 522899-PW, 0.3 μL 522899-PV, 2 μL template DNA and 7.3 μL sterile water.
[0025] Invention Mechanism: By comparing the sequences of vaccine strain MS-H, MS-H re-isolated strains and wild-type MS isolates published in the NCBI database, the present invention found that at 131nt of the gene encoding the hypothetical protein MSH_02330 (MS-H, CP021129.1, 522899nt), the vaccine strain MS-H and its re-isolated strains were A bases, while the wild-type isolates were G bases. It is speculated that the SNP site may be a mutation site unique to the MS-H strain and its re-isolated strains. The present invention establishes a real-time fluorescence quantitative PCR detection method based on the SNP site (A / G).
[0026] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages: Based on the characteristics of the SNP site (A / G) at the 131st nucleotide position of the MSH_02330 gene of the MS-H vaccine strain and the wild strain, the present invention designs a pair of PCR primers that can amplify specific fragments containing the SNP site, and two MGB-Taqman probes that specifically identify the SNP sites of the vaccine strain (MS-H strain) and the wild strain, respectively, and invents a real-time fluorescence quantitative PCR kit that can distinguish between the MS-H vaccine strain (including ts-revertant strain) and the wild strain. In vitro experiments have shown that the kit has high sensitivity, strong specificity and good repeatability, and can not only accurately distinguish between the MS temperature-sensitive vaccine strain (MS-H strain) and the MS wild strain, but also exclude the influence of the ts-revertant strain. The kit can be used to identify the isolated, cultured and purified MS isolates, and can also be used to evaluate the replication efficiency of the MS-H vaccine strain in immunized chickens and monitor the infection of wild viruses. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 The gel electrophoresis result of the PCR amplification product of the fragment where the candidate SNP site is located;
[0028] Figure 2 It is the sequence alignment result of the fragment where the candidate SNP site is located;
[0029] Figure 3 for sequence alignment and primer and probe design;
[0030] Figure 4 The amplification curve of the positive standard corresponding to the gradient dilution of the wild strain;
[0031] Figure 5 It is a standard curve drawn according to the amplification results of the positive standard corresponding to the wild strain;
[0032] Figure 6 The amplification curve of the positive standard corresponding to the gradient diluted vaccine strain;
[0033] Figure 7 It is a standard curve drawn according to the amplification results of the positive standard corresponding to the vaccine strain;
[0034] Figure 8 This is the amplification curve under the FAM fluorescence signal (wild strain) collected separately in the specificity test;
[0035] Fig. 9 Amplification curves under VIC fluorescence signals (vaccine) were collected separately for specific experiments. DETAILED DESCRIPTION
[0036] The following detailed and comprehensive description of the embodiments of the present invention is provided in conjunction with specific examples. Obviously, the described examples are only intended to illustrate a part of the embodiments of the present invention and should not be considered as limiting the scope of the present invention. In the examples, the specific conditions not particularly specified are carried out according to the conditions of normal conditions or manufacturer recommendations. The reagents or instruments used are not indicated by the manufacturer and are all commercially available conventional products.
[0037] Example 1 SNP site screening
[0038] The gene sequences of MS-H strain and its parent strain 86079 / 7NS were downloaded from GenBank. According to the literature (ZHUL, SHAHID MA, MARKHAM J, et al. Comparative genomic analyses of Mycoplasmasynoviae vaccine strain MS-H and its wild-type parent strain 86079 / 7NS: implications for the identification of virulence factors and applications indiagnosis of M.synoviae[J]. Avian pathology: journal of the WVPA, 2019, 48(6): 537-48.), the genes where the 30 SNP sites of MS-H strain and its parent strain 86079 / 7NS were located were found. Using MS-H strain as a reference, the sequences of the corresponding 30 genes in the 25 MS whole genome sequences published in the NCBI database were compared, and 13 SNP sites that were not unique to MS-H and its re-isolated strains were excluded. Subsequently, the remaining 17 SNP sites were screened for sites suitable for establishing a dual-probe identification detection method. The screening conditions were that the CG content in the region where the SNP site was located was high and all MS strains had no other mutations in this region. Finally, four SNP sites that met the conditions were screened, namely 14181nt, 481287nt, 498421nt and 522899nt (MS-H, CP021129.1). According to the conserved regions of the genes where these four SNP sites were located, upstream and downstream primers that could amplify fragments containing the SNP sites were designed, and the primer sequences are shown in Table 1. Fresh culture medium of WVU 1853, MS-H, MG R, and laboratory isolated strains Shandong / 2017-2, NingXia / 2017-1, and Hebei / 2019-1 (ZHANG X, CHEN Y, XIE D, et al. Multi-locus sequence typing analysis of Mycoplasma synoviaeisolates reveals unique sequence types in China[J]. Veterinary microbiology, 2021, 259(109101.) was taken and genomic DNA was extracted by boiling method. Using 6 types of genomic DNA as templates, 4 pairs of primers were used to amplify the corresponding fragments. The amplification results are shown in the figure. Figure 1As shown, the amplified products were sent to Shanghai Sangon Biotechnology Co., Ltd. for sequencing, and then the sequencing results were compared.
[0039] Table 1 Primer sequences for sequencing
[0040]
[0041] The sequencing results of the amplified products are as follows Figure 2 As shown in the figure, the mutations at 14181nt, 522899nt and 481287nt are SNP sites unique to MS-H. The nucleotides at the 498421nt site of Shandong / 2017-2 and MS-H are both C, and the SNP at the 498421nt site is not unique to MS-H. Compared with MS-H, the nucleotide at 481286nt of the MS isolate Hebei / 2019-1 is C instead of A, indicating that there are other mutations near 481287nt, which is not conducive to the establishment of the dual-probe identification detection method. After the mutation at 48181nt of MS-H, the polarity of the translated amino acid did not change (Val→Ile), while the mutation at 522899nt changed the translated amino acid from non-polar to acidic (Gly→Glu). This change may affect the secondary structure of the protein, so the SNP site of 522899nt was selected to establish the dual-probe identification detection method.
[0042] Example 2 Primer and probe design and real-time fluorescence quantitative PCR reaction system and reaction condition optimization
[0043] 1. Primer and probe design
[0044] Taking the MS-H strain as a reference, a pair of universal upstream and downstream primers that can amplify the fragment containing the SNP site were designed based on the conserved region of the gene MSH_02330 (MS-H, CP021129.1) of all MS full genome sequences published in the NCBI database. They were named 522899-F2 and 522899-R3, respectively. The sequences are shown in SEQ ID NO.1 and SEQ ID NO.2, respectively, and the product size is 122bp. The wild strain-specific probe 522899-PW and the vaccine strain-specific probe 522899-PV were designed for the nucleotide difference at the SNP site at position 131, respectively, and the sequences are shown in SEQ ID NO.3 and SEQ ID NO.4, respectively. The 5′ end of the probe 522899-PW is labeled with a FAM reporter group, the 5′ end of the probe 522899-PV is labeled with a VIC reporter group, and the 3′ ends of both probes are labeled with an MGB quencher group. The primers and probes were synthesized by Nanjing GenScript Biotechnology Co., Ltd., and the sequences are shown in Table 2.
[0045] Table 2 Primer and probe sequences
[0046]
[0047] 2. Optimization of real-time fluorescence quantitative PCR reaction system and reaction conditions
[0048] The synthesized primers and probes were diluted with ultrapure water to a concentration of 10 μM.
[0049] The reaction system of fluorescent quantitative PCR is 20 μL, including 2 μL DNA template, 10 μL 2×qPCR Probe Master Mix, and the upstream and downstream primers are set to 0.1 μL, 0.2 μL, 0.4 μL, 0.8 μL, and 1.8 μL five gradients, and both probes are 0.2 μL. Fluorescent quantitative PCR detection is performed, and the results are shown in Table 3. The minimum primer amount when the Ct value is the smallest and the non-specific signal is the lowest is 0.1 μL each. Under this condition, the amount of the two probes is set to 0.2 μL, 0.3 μL, 0.4 μL, and 0.5 μL. The optimal addition amount of the two probes is screened by the matrix method to determine the optimal probe ratio with the smallest sample detection Ct value and the lowest non-specific signal. The results are shown in Table 4. The optimal amounts of 522899-PW and 522899-PV are 0.2 μL and 0.3 μL, respectively. The reaction conditions of all reactions are carried out according to the instructions of 2×qPCR Probe Master Mix. The reaction conditions were: 95°C for 5 min; 95°C for 10 s, 60°C for 30 s, 45 cycles; and signal collection at 60°C for 30 s.
[0050] Table 3 Determination of the optimal amount of primers added
[0051]
[0052] Table 4 Determination of the optimal probe addition amount
[0053]
[0054] In summary, it can be seen from this embodiment that the PCR amplification system is 20 μL, which includes 10 μL 2×qPCR ProbeMaster Mix, 0.1-1.8 μL 522899-F, 0.1-1.8 μL 522899-R, 0.2-0.5 μL 522899-PW, 0.2-0.5 μL 522899-PV, 2 μL template DNA and sterile water, and fluorescence signals can be detected.
[0055] By optimizing different combinations of primers and probe concentrations, the optimal fluorescence quantitative PCR reaction system was determined to be 20 μL. The reaction system included 10 μL 2×qPCR Probe Master Mix, 0.1 μL 522899-F, 0.1 μL 522899-R, 0.2 μL 522899-PW, 0.3 μL 522899-PV, 2 μL template DNA and 7.3 μL sterile water. The reaction conditions were: 95°C for 5 min; 95°C for 10 s, 60°C for 30 s, for a total of 40 cycles, and the signal was collected at the 60°C for 30 s stage.
[0056] Example 3 Establishment of a real-time fluorescence quantitative PCR method for distinguishing wild-type MS strains from vaccine strains (MS-H) 1. Preparation of positive standards for real-time fluorescence quantitative PCR detection
[0057] The genomic DNA of the wild strain of MS (WVU1853 strain, CP011096.1) and the vaccine strain of MS-H (CP021129.1) (the vaccine strain of MS-H was purchased from Australian Bioresources) was used as a template, and the corresponding MSH_02330 gene fragment was amplified using primer pairs 522899-F2 (SEQ ID NO.1) and 522899-R2 (SEQ ID NO.5), and the sequences were shown in SEQ ID NO.8 and SEQ ID NO.9, respectively. After the amplified products were recovered, they were cloned into the pEASY-Blunt Simple Cloning Vector vector (Beijing Quanshijin Biotechnology Co., Ltd., catalog number: CB111) and the sequences were shown in SEQ ID NO.10 and SEQ ID NO.11, and transformed into the competent cells of Escherichia coli Trans1-T1 (Beijing Quanshijin Biotechnology Co., Ltd., catalog number: CD501-02) to prepare positive standards.
[0058] 2. Establishment of standard curve and sensitivity test of real-time fluorescence quantitative PCR method
[0059] The positive plasmids corresponding to the vaccine strain and the wild strain were extracted from E. coli using a high-purity plasmid extraction kit (Congwei Century Biotechnology Co., Ltd., product number: CW0500M) as the positive standard for the vaccine strain and the wild strain, respectively. According to the formula N = (C × 10 -9 ) / (3991×660)×6.02×10 23 (where C is the concentration of the standard) to calculate the number of plasmid copies. 8 copies / μl to 10 1The 10-fold series of copies / μl was used to establish the standard curve of the real-time fluorescence quantitative PCR method. The real-time fluorescence quantitative PCR amplification experiment was carried out using the optimized conditions. The PCR reagents used were qPCR Probe Master Mix (Nanjing Novozyme Biotechnology Co., Ltd., product number: Q112). The amplification curve and standard curve of the wild-type positive standard are shown in Figure 4 and Figure 5 The amplification curve and standard curve of the vaccine strain (MS-H) positive standard are shown in Figure 6 and Figure 7 According to the data in the figure, the detection sensitivity of the real-time fluorescence quantitative PCR method for the two positive standards is 10 1 copies / μl, Cq value has a good linear relationship with sample concentration. The standard curve of vaccine strain MS-H is: y=-3.34x+39.72, R 2 =0.999, the amplification efficiency is 99.44%; the standard curve of the wild strain is: y=-3.34x+38.45, R 2 =0.999, and the amplification efficiency is 99.92%.
[0060] 3. Specificity test
[0061] The wild-type MS strain (WVU 1853 strain, number: CVCC385) and Mycoplasma gallisepticum (MG) F strain (number: CVCC1652) were purchased from the China Veterinary Microbiological Culture Collection (http: / / cvcc.ivdc.org.cn), and the MS-H vaccine strain was purchased from Australian Bioresources. Genomic DNA was extracted from the cultures of WVU1853 strain, MS-H strain, and Mycoplasma gallisepticum (MG) F strain, respectively, and used as templates to perform real-time fluorescence quantitative PCR experiments according to the optimized experimental system and conditions to verify the specificity of the optimized fluorescence quantitative method. The sample using the genomic DNA of the wild-type MS strain (WVU1853 strain) as a template could only detect the fluorescence signal of the wild-type strain-specific probe 522899-PW, but could not detect the fluorescence signal of the vaccine strain-specific probe 522899-PV. The results are shown in Table 1. Figure 8 Using the genomic DNA of the MS-H vaccine strain as a template, only the fluorescence signal of the vaccine strain-specific probe 522899-PV could be detected, but the fluorescence signal of the wild strain-specific probe 522899-PW could not be detected. Fig. 9The two probe signals were not detected when MG (F strain) genomic DNA was used as a template. The above results show that the real-time fluorescence quantitative PCR method for distinguishing MS wild strains and MS-H vaccine strains established in the present invention has good specificity and can accurately distinguish and detect pure cultured MS wild strains and vaccine strains.
[0062] 4. Repeatability test
[0063] Three different concentrations of vaccine strain positive standards and wild strain positive standards were used as templates to conduct intra-group and inter-group parallel tests. The intra-group parallel test method is that each sample is repeated three times in one PCR test; the inter-group parallel test method is that each sample is tested in three different batches. The intra-group and inter-group coefficients of variation were calculated to analyze the repeatability of the test. The experimental results showed that the intra-group and inter-group coefficients of variation of the fluorescence quantitative PCR detection method were both lower than 2.5%, with good repeatability. The repeatability test results of the positive standards corresponding to the wild strain are shown in Table 5, and the repeatability test results of the positive standards corresponding to the vaccine strain are shown in Table 6.
[0064] Table 5 Repeatability test of wild strain detection
[0065]
[0066] Table 6 Repeatability test of vaccine strain detection
[0067]
[0068] 5. Detection of mixed samples
[0069] The wild-type positive standard substances of different concentrations were mixed with sterile water and vaccine strain positive standard substances in equal amounts, and the test was performed according to the method of step 2. The results are shown in Table 7. Similarly, the vaccine strain positive standard substances of different concentrations were mixed with sterile water and wild-type positive standard substances in equal amounts, and the test was performed according to the method of step 2. The results are shown in Table 8. It can be seen from Tables 7 and 8 that when the concentrations of the wild-type strain and the vaccine strain are similar or the concentrations differ by 10 times, the presence of both can still be detected at the same time. This shows that the kit has a certain anti-interference ability and can accurately distinguish and quantify the wild-type strain and the vaccine strain when they exist at the same time.
[0070] Table 7 Results of interference test of vaccine strains on wild strain detection
[0071]
[0072] Table 8 Results of interference test of wild strains on vaccine strain detection
[0073]
[0074]
[0075] Example 4 Application of Real-time Fluorescence Quantitative PCR Kit for Identifying MS Wild-type Strains and Vaccine Strains (MS-H) in Clinical Sample Detection
[0076] Random sampling and testing were carried out on three large-scale chicken farms that had been immunized with MS-H live vaccine. The method used was to collect chicken cleft palate swab samples with sterile cotton swabs, a total of 79 samples. The DNA in the samples was extracted using the boiling method. The specific steps are as follows: Place the sample in 1ml of normal saline and shake the bacteria to fall off into the normal saline. Pipette 700μL of the shaken solution into a new 1.5ml centrifuge tube, centrifuge at 12000r / min for 10 minutes, and discard 600μL of the supernatant. After resuspending the remaining solution, boil it in a 100℃ metal bath for 10 minutes to obtain genomic DNA.
[0077] First, the samples were tested using the broad-spectrum real-time fluorescence quantitative PCR method reported by Sprygin AV et al. (SPRYGIN AV, ANDREYCHUK DB, KOLOTILOV AN, et al. Development of a duplex real-time TaqMan PCR assay with an internal control for the detection of Mycoplasma gallisepticum and Mycoplasma synoviae in clinical samples from commercial and backyard poultry [J]. Avian pathology: journal of the WVPA, 2010, 39 (2): 99-109.). This method targets the vlhA gene and can detect both wild-type and vaccine strains of MS. In the test, as long as the Cq value is not 0, it is judged as positive. This method is called a non-differentiation method. Then, the qPCR identification and detection method for MS wild strains and vaccine strains based on the obg gene SNP site design invented by Zhang Xiaorong et al. (Zhang Xiaorong, Chen Mengyao, Wu Yantao, et al. A real-time fluorescence quantitative PCR kit for identifying synoviae wild strains and vaccine strains MS-H, CN110699469B[P / OL].2022-08-09].) and the kit described in the present invention were used to perform identification and detection of wild strains and vaccine strains on the batch of samples. The experimental conditions refer to the optimized system and conditions in Example 2. For the single MS-H strain positive sample DNA and the single wild strain positive sample DNA in the qPCR test results, PCR amplification was performed using vlhA genotyping primers Link (sequence such as SEQ ID NO.6) and MSConsR (sequence such as SEQ ID NO.7) (JEFFERY N, GASSER RB, STEER PA, et al. Classification of Mycoplasma synoviae strains using single-strand conformation polymorphism and high-resolution melting-curve analysis of the vlhA gene single-copy region [J]. Microbiology (Reading), 2007, 153 (Pt 8): 2679-88.), and the amplified product was sent to Shanghai Shenggong Biotechnology Technology Service Co., Ltd. for sequencing. The detection and sequencing results are shown in Table 9.
[0078] Table 9 Clinical sample test results
[0079]
[0080]
[0081]
[0082] This kit identified 59 samples as MS-H and 20 samples as wild-type MS strains. The qPCR identification method designed based on the obg gene SNP site showed that 32 samples contained wild-type MS strains and 54 samples contained MS-H vaccine strains. The vlhA gene sequencing typing results showed that 59 samples were type C, and their sequences were consistent with the MS-H strain; 20 samples were type K, identified as wild-type MS strains. The vlhA gene sequencing typing results were completely consistent with this kit. The identification accuracy of this kit for wild-type MS strains and MS-H vaccine strains was 100%, while the qPCR identification method designed based on the obg gene SNP site had an identification accuracy of 93.67% for this batch of samples. The identification accuracy of this kit is higher than that of the qPCR identification method designed based on the obg gene SNP site.
Claims
1. An application of a primer-probe combination based on a SNP site between an MS-H vaccine strain and a wild strain in the preparation of a kit for identifying a wild strain of Mycoplasma synoviae and a temperature-sensitive vaccine strain, wherein the SNP site is at position 131 of the MSH_02330 gene, the polymorphic site of the wild strain of Mycoplasma synoviae is G, and the polymorphic site of the temperature-sensitive vaccine strain is A. The primer pair sequences in the primer-probe combination are shown in SEQ ID NO.1 and SEQ ID NO.2, and the probe sequences in the primer-probe combination are shown in SEQ ID NO.3 and SEQ ID NO.4, respectively.
2. A primer-probe combination for distinguishing wild-type strains of Mycoplasma synoviae and temperature-sensitive vaccine strains, characterized in that: The primer pair sequences in the primer-probe combination are shown as SEQ ID NO.1 and SEQ ID NO.2, and the probe sequences in the primer-probe combination are shown as SEQ ID NO.3 and SEQ ID NO.4, respectively.
3. A kit for distinguishing wild-type strains of Mycoplasma synoviae and temperature-sensitive vaccine strains, characterized in that: It comprises the primer-probe combination according to claim 2.
4. The kit according to claim 3, characterized in that The 5'-end of the probe is labeled with FAM and VIC reporter groups, respectively, and the 3'-end is labeled with MGB fluorescence quenching group.
5. The kit according to claim 3, characterized in that The kit also includes a 2×qPCR amplification premix and a positive standard.
6. The kit according to claim 5, characterized in that The positive standard includes a plasmid containing the MSH_02330 gene fragment of the wild strain WVU 1853 and the vaccine strain MS-H strain of Mycoplasma synoviae.
7. The kit according to claim 6, characterized in that The sequences of the MSH_02330 gene fragments of the wild strain WVU 1853 and the vaccine strain MS-H are shown in SEQ ID NO.8 and SEQ ID NO.
9.
8. The kit according to any one of claims 4 to 7, characterized in that When used to differentiate between field strains of M. synoviae and temperature-sensitive vaccine strains, follow these steps: (1) Extracting total DNA from the sample to be tested; (2) establishing a fluorescence quantitative standard curve, using a gradient dilution of the positive standard plasmid as a template, and performing fluorescence quantitative PCR amplification with the primer-probe combination described in claim 2 to establish a standard curve; (3) using the total DNA extracted in step (1) as a template, and performing fluorescent quantitative PCR amplification using the primer pair and probe described in claim 2; (4) Fluorescence signals are automatically detected and collected during the PCR reaction. Signals only in the FAM channel are identified as wild-type strains, and signals only in the VIC channel are identified as MS-H vaccines. At the same time, the pathogen content in the sample to be tested is quantified according to the standard curve.
9. The kit according to claim 8, characterized in that The reaction conditions of step (2) fluorescence quantitative PCR were as follows: 95°C for 5 min; 95°C for 10 s, 60°C for 30 s, 40 cycles, and the signal was collected at 60°C for 30 s.
10. The kit according to claim 8, characterized in that The PCR amplification system in step (2) is 20 μL, which contains 10 μL 2×qPCR Probe Master Mix, 0.1~1.8 μL 522899-F, 0.1~1.8 μL 522899-R, 0.2~0.5 μL 522899-PW, 0.2~0.5 μL 522899-PV, 2 μL template DNA and sterile water.
Citation Information
Patent Citations
Real-time fluorescence quantitative PCR (polymerase chain reaction) kit for identification of mycoplasma synoviae wild strain and vaccine strain MS-H
CN110699469A
Kit and detection method for identifying mycoplasma synoviae vaccine strain MS-H and wild strain
CN117265146A
Cited By
SNP (Single Nucleotide Polymorphism) site for distinguishing Mycoplasma synoviae MS-H vaccine strain and wild strain, kit and application
CN119372348A
SNP site for distinguishing mycoplasma synoviae ms-h vaccine strain from wild strain, kit and application
CN119372348B
Primer probe combination for detecting avian mycoplasma, kit, detection method and application
CN120060519A
Primer probe combination, kit, detection method and application for detecting avian mycoplasma
CN120060519B
LAMP (Loop-Mediated Isothermal Amplification) primer probe composition and kit for identifying MS-H strain and wild strain of chicken mycoplasma synoviae
CN122303461A
